PT027 Compared to PT007 in Patients With Asthma With Mannitol-induced Acute Airway Obstruction

Inclusion Criteria: * Participants who have been diagnosed with asthma \> 6 months before Visit 1 by a physician. * Participants must have been prescribed and using as-needed SABA as only asthma treatment for at least 4 weeks before screening visit. * Participants should have pre-bronchodilator FEV1 ≥ 1.5 L and FEV1 ≥ 60% to \< 90% predicted normal at Visit 1. * Participants should have a positive response to mannitol challenge performed at Visit 1 (a decrease in FEV1 by at least 15% \[PD15\] at ≤ 635 mg). * Participants should return to within 10% of baseline FEV1 (≥ 90% of baseline FEV1), within 1 hour after positive mannitol challenge and 4 inhalations of PT007, performed at Visit 1. * Participants should be able to adhere to study procedures in the judgment of the Investigator. * Male or female. * Women of childbearing potential must have a negative urine pregnancy test at each study visit. * Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the Informed Consent Form (ICF) and in this protocol. * Provision of signed and dated written Optional Genetic Research Information informed consent prior to collection of samples for optional genetic research that supports Genomic Initiative. Exclusion Criteria: * Any evidence of clinically significant lung disease other than asthma. * If the participant has had any face-to-face unscheduled or urgent visit for asthma worsening within the last 4 weeks. * Any signifi…